GUEST COLUMNISTS

  • The Endless Possibilities Of Closed-Loop RNA

    The world of RNA now encompasses multiple types of RNA, and circular RNA is a particularly intriguing format.

  • Meet Hearables, The Next Revolutionary Medical Devices

    Hearables, in-ear devices that use sensors to monitor health, are poised to become the next revolutionary technology. Jacob Skinner, CEO of U.K.-based wearable technology design and development consultants Thrive Wearables, discusses its possibilities. 

  • Qualification Considerations For A “Factory-in-a-Box”

    The cell therapy market is rapidly expanding into a multibillion-dollar industry, but its production is cost-prohibitive due to the limited manufacturing space and number of personnel required, while capacity is not easily scalable and is limited by processing time. Enter the "factory-in-a-box," which can be a game-changer for the industry.
     

  • Patenting Antibodies: The 4 Tactics To Use In 2021

    With epitope claims less available post-Amgen v. Sanofi, this article examines four useful approaches that you and your antibody patent lawyer can implement in order to improve your chances of obtaining valid antibody claims with functional attributes.

  • RNA Cell Therapy: A New Class of Advanced Therapies

    RNA cell therapy is a new class of advanced therapies now in clinical trials to treat an array of diseases in and beyond oncology.

  • What Do Artificial Intelligence And Continuous Validation Have In Common?

    Validation documentation can be reduced by applying automated testing and deployment. This article discusses ISO standards that address risk management, IT alignment with software engineering, opportunities for continuous lifecycle management, and how artificial intelligence (AI) can help.

  • The Role Of The Contract Manufacturer Under The EU MDR & IVDR

    As of May 26, 2021, medical device companies must now comply with the EU's Medical Device Regulation (MDR) requirements, and the In Vitro Diagnostics Regulation (IVDR) requirements are effective in May 2022. This article examines the role of the contract manufacturer under these regulations.

  • Outlook: Biotech In 2021 & Beyond

    Biopharma companies have responded in an astounding manner to the COVID-19 pandemic through vaccines, therapies, diagnostics, and variant tracking. For those efforts, the industry is seeing some amazing investor awareness, political support, and increased public perception. This article focuses on the U.S., but also includes some worldwide numbers.

PHARMA OUTSOURCING WHITE PAPERS

louis-new

COVID-19 AND YOUR SUPPLY CHAINS

The Latest Analysis And Advice From Outsourced Pharma

OUTSOURCED PHARMA CONTENT COLLECTIONS

21_03_OP_WPAanalyses_Ebook_300x200

 

Quality, Supply Chain Agility, Analytical Development: These are the subjects of three thought-provoking whitepapers on our biopharma industry, reviewed and analyzed for Outsourced Pharma readers by Chief Editor Louis Garguilo. Important in their own right, see how Garguilo pulls out the most salient points from the reports to help readers increase your understanding and efficacy of drug development and manufacturing outsourcing.

More Content Collections

SPOTLIGHT JOB OPENING: TARSUS

tarsus-job1

Tarsus, a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, is hiring a VP Manufacturing Operations & Supply Chain Management. Reporting to the COO, you will be accountable for the overall CMC development, manufacturing and supply chain strategy for clinical and commercial supply of drug substance, drug product and IMP.

Sound interesting?

Read the Job Posting to learn more.